Nesina

Physical Activity, Type 2 Diabetes, Diet
Treatment
4 FDA approvals
20 Active Studies for Nesina

What is Nesina

AlogliptinThe Generic name of this drug
Treatment SummaryAlogliptin is an oral medication that helps control blood sugar levels by inhibiting the activity of the enzyme dipeptidyl peptidase-4 (DPP-4). It is available as a benzoate salt and is mainly composed of the R-enantiomer. Alogliptin was approved by the FDA in 2013 and does not convert to the S-enantiomer when taken.
Nesinais the brand name
image of different drug pills on a surface
Nesina Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nesina
Alogliptin
2013
26

Approved as Treatment by the FDA

Alogliptin, also known as Nesina, is approved by the FDA for 4 uses which include Type 2 Diabetes Mellitus and Physical Activity .
Type 2 Diabetes Mellitus
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
Physical Activity
Used to treat Exercise in combination with Pioglitazone
Type 2 Diabetes
Used to treat Type 2 Diabetes Mellitus in combination with Pioglitazone
Diet
Used to treat Diet in combination with Pioglitazone

Effectiveness

How Nesina Affects PatientsAlogliptin starts to reduce the levels of an enzyme (DPP-4) within 2-3 hours after being taken, and it continues to keep levels low for up to 24 hours with doses of 25 mg or higher. It also helps to lower glucagon and increase levels of a hormone (GLP-1) that helps regulate blood sugar levels. Taking alogliptin will not affect the time it takes for your heart to beat.
How Nesina works in the bodyAlogliptin helps control blood sugar levels by blocking an enzyme called dipeptidyl peptidase 4 (DPP-4). This enzyme usually breaks down the hormones GIP and GLP-1, which stimulate insulin production. Alogliptin prevents this breakdown, so more of these hormones are in the blood. This increases insulin production, suppresses glucagon production, and helps with feelings of fullness.

When to interrupt dosage

The amount of Nesina is contingent upon the established affliction, including Diet, Physical Activity and Type 2 Diabetes. The dosage is subject to the mode of delivery (as outlined in the table below).
Condition
Dosage
Administration
Diet
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral
Type 2 Diabetes
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral
Physical Activity
, 6.25 mg, 12.5 mg, 25.0 mg
, Tablet - Oral, Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Nesina.
Common Nesina Drug Interactions
Drug Name
Risk Level
Description
Amitriptyline
Major
The metabolism of Amitriptyline can be decreased when combined with Alogliptin.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Alogliptin.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Alogliptin.
Clomipramine
Major
The metabolism of Clomipramine can be decreased when combined with Alogliptin.
Clonidine
Major
The metabolism of Clonidine can be decreased when combined with Alogliptin.
Nesina Toxicity & Overdose RiskAlogliptin overdose may lead to common side effects such as a sore throat, headache, and respiratory infection. These symptoms occur in at least 4% of those who take alogliptin and more often than in those taking a placebo.

Nesina Novel Uses: Which Conditions Have a Clinical Trial Featuring Nesina?

196 active studies are in progress to assess the potential of Nesina for improving Physical Activity, managing Type 2 Diabetes and providing Dietary benefits.
Condition
Clinical Trials
Trial Phases
Diet
5 Actively Recruiting
Not Applicable, Phase 1
Physical Activity
24 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Type 2 Diabetes
167 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Nesina Reviews: What are patients saying about Nesina?

5Patient Review
11/11/2013
Nesina for Type 2 Diabetes Mellitus
This medication has been extremely effective for me. I take it along with a low dose of Amaryl each day, and my A1C level has dropped from 7.3 to 5.9 in just three months!
1Patient Review
9/13/2016
Nesina for Type 2 Diabetes Mellitus
After taking Januvia for many years, my insurance company made me switch to Nesina. My blood sugar has been spiking since I started taking it, and I've already switched back to Januvia at my own expense.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nesina

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the medication Nesina used for?

"An injectable medication, Alogliptin is used to help manage blood sugar levels in people with type 2 diabetes. When combined with a proper diet and exercise regimen, this medication can help to prevent the onset of serious complications from diabetes, such as kidney damage, blindness, nerve problems, loss of limbs, and sexual dysfunction."

Answered by AI

Does Nesina have metformin in it?

"The drugs in Nesina Met are alogliptin and metformin hydrochloride. Alogliptin is given in a dose of 12.5 mg per 1000 mg metformin hydrochloride."

Answered by AI

What is the difference between Januvia and Nesina?

"If you're struggling to get your blood sugar under control, Januvia (sitagliptin) could be a good addition to your treatment plan. Januvia lowers blood sugar levels and is taken orally, so you don't have to worry about injections. Nesina (alogliptin) is another option for oral treatment, but it's not as effective as Januvia."

Answered by AI

Does Nesina cause weight gain?

"Nesina will not make you gain weight. It helps the body to produce more insulin when blood sugar is high, and also tells the liver to reduce sugar production."

Answered by AI

Clinical Trials for Nesina

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Nesina clinical trials? We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Nesina clinical trials? We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Nesina clinical trials? We made a collection of clinical trials featuring Nesina, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security